

1 **White matter lesions as a prognostic marker of recurrence in**
2 **cryptogenic stroke with high-risk patent foramen ovale**

3
4 Shunichi Niiyama, MD¹; Yuji Ueno*, MD, PhD¹; Naohide Kurita, MD, PhD²;
5 Sho Nakajima, MD, PhD²; Chikage Kijima, MD¹;
6 Kenichiro Hira, MD, PhD¹; Nobukazu Miyamoto, MD, PhD¹; Masao Watanabe, MD, PhD²;
7 Kazuo Yamashiro, MD, PhD²; Takao Urabe, MD, PhD²; Nobutaka Hattori, MD, PhD¹

8
9
10 ¹ Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo,
11 Bunkyo-ku, Tokyo 113-8421, Japan

12 ² Department of Neurology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka,
13 Urayasu, Chiba 279-0021, Japan

14 ³ Department of Medical Technology Innovation Center, Juntendo University School of
15 Medicine, Tokyo, Japan.

16
17 ***Correspondence to:** Yuji Ueno

18 Department of Neurology, Juntendo University, Faculty of Medicine,

19 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan

20 Tel: +81-3-3813-3111; Fax: +81-3-5800-0547

21 E-mail: yuji-u@juntendo.ac.jp

22
23 **Running title:** White matter lesions and high-risk PFO

24 **Keywords:** transesophageal echocardiography, patent foramen ovale, right-to-left shunt,
25 stroke recurrence

26
27
28 Word count: 302(abstract) and 5193 words (total)

29 Total number of references: 26, tables: 5, figures: 3

30

1 **Abstract**

2 **Introduction:** Atrial septal aneurysms increase the risk of stroke recurrence in
3 cryptogenic stroke patients with a patent foramen ovale. Factors related to stroke
4 recurrence according to the patent foramen ovale risk stratification have not been fully
5 evaluated.

6 **Methods:** Data from a multicenter observational registry of ischemic stroke patients
7 undergoing transesophageal echocardiography, with a comprehensive database
8 including clinical characteristics and long-term prognosis, were used for this study.
9 Patients were classified into three groups: high-risk patent foramen ovale group, large
10 shunt patent foramen ovale (≥ 20 microbubbles) or patent foramen ovale with atrial
11 septal aneurysm; right-to-left shunt group, right-to-left shunt including patent foramen
12 ovale with < 20 microbubbles or without atrial septal aneurysm; and negative right-to-
13 left shunt group. Among stroke subtype, factors related to stroke recurrence were
14 investigated according to the risk stratification of patent foramen ovale in cryptogenic
15 stroke.

16 **Results:** In total, 586 patients (185 females; 65.5 ± 13.2 years) were analyzed. In
17 cryptogenic stroke (329 patients) with median follow-up of 4.2 (interquartile range, 1.0–
18 6.1) years, 55 patients had stroke recurrence. The negative right-to-left shunt, right-to-
19 left shunt, and high-risk patent foramen ovale groups included 179, 90, and 60 patients,
20 in which stroke recurrence occurred in 5.3%, 2.5%, and 4.6% per person-year,
21 respectively. In patients with high-risk patent foramen ovale, the NIH stroke scale score
22 (hazard ratio 1.257, 95% CI 1.034-1.530, $P=0.022$) and periventricular hyperintensity
23 (hazard ratio 3.369, 95% CI 1.103-10.294, $P=0.035$) were predictive markers for stroke

1 recurrence on multivariate Cox Hazards analysis, but no factors were related to stroke
2 recurrence in the right-to-left shunt and negative right-to-left shunt groups.
3 **Conclusion:** High-risk patent foramen ovale is an important embolic source in
4 cryptogenic stroke. Periventricular hyperintensity was shown to predict recurrent stroke
5 in patients with a high-risk patent foramen ovale. In such cases, percutaneous patent
6 foramen ovale closure might be effective at <60 years of age.

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

1 **Introduction**

2 The foramen ovale, a remnant of the fetal circulation, can still be open in about 25%
3 of the general adult population.^{1,2} A patent foramen ovale (PFO) has been shown to be
4 a risk factor for ischemic stroke, particularly in young subjects. A recent meta-analysis
5 showed that a PFO was found in 29% of cryptogenic stroke case, two times higher than
6 that in patients with stroke of known cause.³ Furthermore, the coexistence of an atrial
7 septal aneurysm increased the risk of stroke recurrence in patients with a PFO.⁴
8 Meanwhile, a PFO has been shown to increase the risk of recurrent stroke even in
9 elderly subjects.⁵ Transesophageal echocardiography (TEE) is not only the gold
10 standard for detecting a PFO with a degree of right-to-left (RLS) shunt, but also useful
11 for other cardiac anomalies such as atrial septal aneurysms (ASAs).⁶ It has been shown
12 that a high-risk PFO, assessed by TEE as having an ASA and high shunt volume, was a
13 predictor for stroke recurrence, in which PFO closure was useful.⁷⁻¹⁰ So far, predictors
14 of stroke recurrence in cryptogenic stroke patients according to the PFO risk
15 stratification have not been fully studied.

16 A multicenter registry enrolled patients with brain infarction and transient ischemic
17 attack (TIA) with a comprehensive database including baseline characteristics,
18 laboratory data, radiological findings, therapy, and long-term prognosis, for whom
19 potential embolic etiologies including PFO and ASA were evaluated by TEE. Taking
20 advantage of this registry, the factors related to recurrent stroke in cryptogenic stroke
21 patients with high-risk PFO, with RLS other than high-risk PFO, and without RLS,
22 were investigated.

23

24 **Methods**

1 **Study population**

2 The registry was a multicenter, observational registry retrospectively enrolling
3 consecutive patients with ischemic stroke who underwent TEE in Juntendo University
4 Hospital and Juntendo University Urayasu Hospital from February 2012 to December
5 2017 (COCTAIL-TEE [Clinical Observation, Characteristics, and prognosis for long-
6 term of stroke patients undergoing TransEsophageal Echocardiography]). The inclusion
7 criteria for this registration were as follows: (1) patients with brain infarction and TIA,
8 (2) stroke patients underwent TEE. The patients' medical history and diagnostic
9 modalities including magnetic resonance imaging (MRI), 12-lead electrocardiography,
10 blood examinations, and TEE performed during admission were evaluated. Treatment
11 with anti-thrombotic agents and long-term outcomes such as stroke recurrence after
12 hospital discharge were retrospectively analyzed. The institutional review boards of
13 both participating hospitals approved the study protocol. Clinical information obtained
14 from medical records was used; thus, the need to obtain written, informed consent from
15 each patient was waived in this retrospective study. This study was conducted in
16 accordance with the Declaration of Helsinki.

17 **Atherosclerotic risk factors**

18 Hypertension was defined as systolic blood pressure >140 mmHg or diastolic blood
19 pressure >90 mmHg after the 14th admission day or use of antihypertensive drugs.
20 Diabetes mellitus was defined as hemoglobin A1c levels $\geq 6.5\%$ on admission or the use
21 of antidiabetic drugs. Dyslipidemia was defined as low-density lipoprotein cholesterol \geq
22 140 mg/dl, high-density lipoprotein cholesterol < 40 mg/dl, triglycerides ≥ 150 mg/dl,
23 or the use of lipid-lowering drugs. Ischemic heart disease included myocardial

1 infarction, angina pectoris, and coronary artery stenosis. Chronic kidney disease was
2 defined as an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m².

3 **MRI sequences**

4 MRI was performed at each institution with 1.5- or 3-T scanners during
5 hospitalization. Sequences included axial diffusion-weighted imaging (DWI), fluid-
6 attenuated inversion recovery imaging (FLAIR), magnetic resonance angiography
7 (MRA), and the GRE T2* sequence. DWI (repetition time (TR) / echo time (TE)
8 =4156-7000/60-120 ms) was used to assess the size and distribution of the index stroke
9 lesions. FLAIR (TR/TE =6879-10000/105-120 ms) was used to evaluate the degree of
10 deep and subcortical white matter hyperintensity (DSWMH) and periventricular
11 hyperintensity (PVH) in accordance with Fazekas grades 0-3.¹¹ MRA (TR/TE = 19-
12 30/2.8-6.9 ms) was used to detect intracranial stenosis >50% not relevant to the
13 infarction area. Examinations were performed by two or three experienced sonographers
14 in each institution.

15 **TEE study**

16 TEE was performed as explained in our previous work.¹² An ASA was defined as a
17 ≥10-mm excursion into either the left or right atrium, or a sum of total excursion into
18 the left or right atrium of ≥15 mm. The right-to-left shunt (RLS) was assessed by
19 injecting agitated saline and having patients perform the Valsalva maneuver.
20 Subsequently, the number of microbubbles with and without contrast agents was
21 compared, and the number transiting from the right to the left atrium was counted. PFO
22 was diagnosed when microbubbles were visualized in the left atrium ≤3 cardiac cycles
23 after the Valsalva maneuver, whereas a pulmonary arteriovenous fistula was diagnosed
24 when microbubbles were visualized in the left atrium >3 cardiac cycles after the

1 Valsalva maneuver or when microbubbles were visualized without the Valsalva
2 maneuver.

3 **Classification of patients based on the presence of RLS**

4 Based on the presence or absence of RLS, patients were classified into three groups:
5 negative RLS group, lacking RLS; RLS group, RLS including a PFO or pulmonary
6 arteriovenous fistula with a small-to-moderate shunt (<20 microbubbles) or without
7 ASA; and high-risk PFO group, having a large-shunt PFO (≥ 20 microbubbles) or
8 concurrent ASA.

9 **Data collection for analyses and outcome measures**

10 Baseline clinical information and radiological and echocardiographic data during
11 hospitalization were collected through hospital charts or database reviews. During the
12 study period from May 2021 to December 2021, such data were retrospectively
13 obtained. The primary outcome of stroke recurrence, for any type of stroke occurrence
14 such as brain infarction, transient ischemic attack, intracranial hemorrhage, and
15 subarachnoid hemorrhage, was also extracted from hospital charts or database reviews.
16 In enrolled patients, ischemic stroke subtype was determined according to the Trial of
17 Org 10172 in Acute Stroke Treatment (TOAST) criteria.¹³ Clinical characteristics were
18 compared between cryptogenic stroke and other stroke subtype, and factors related to
19 stroke recurrence were investigated in the negative RLS, RLS, and high-risk PFO
20 groups, in cryptogenic stroke.

21 **Statistical analysis**

22 Data are presented as number (%), mean \pm standard deviation, and median
23 (interquartile range) values. Patients' characteristics and baseline data were compared
24 between the two groups. Continuous variables were compared using the Mann-Whitney

1 test, and nominal variables were analyzed by the chi-squared test. The incidence of
2 recurrent stroke was estimated per 100 person-years of observation by negative RLS,
3 RLS, and high-risk PFO in cryptogenic stroke. The Cox proportional hazards model
4 was used to explore factors associated with recurrent stroke. After univariate analysis of
5 all clinically relevant covariates, those with a $P < 0.2$ were included in the multivariable
6 Cox model. The Kaplan-Meier method and log-rank test were used to estimate
7 cumulative event rates of recurrent vascular events. Missing data were handled with
8 pairwise deletion. Significance (P value) was set at < 0.05 . Statistical analyses were
9 conducted using IBM SPSS Statistics version 27 (IBM, Armonk, NY, USA).

10 **Data availability statement**

11 The datasets used and analyzed during the current study are available from the
12 corresponding author on reasonable request.

13

14 **Results**

15 A total of 598 patients with ischemic stroke and TIA were enrolled in the COCTAIL-
16 TEE registry from two hospitals in Japan. Of these, seven patients whose follow-up data
17 were unavailable and five patients who were not evaluated for the presence of RLS
18 during TEE examinations were excluded. Thus, the data of 586 patients (185 females;
19 65.5 ± 13.2 years) with median follow-up of 4.2 (interquartile range, 1.0–6.3) years
20 were analyzed (Fig. 1).

21

22 **Clinical characteristics of patients with cryptogenic stroke and other stroke**
23 **subtype**

1 Overall, 329 patients were categorized as having cryptogenic stroke, and 257 patients
2 had other stroke subtypes, consisting of 70 patients with transient ischemic attack, 54
3 patients with small artery occlusion, 78 patients with large artery atherosclerosis, 42
4 with cardioembolism, and 13 with other determined etiology including branch
5 atheromatous disease (Fig. 1). Table 1 summarizes the clinical characteristics of patients
6 with cryptogenic stroke compared with other stroke subtypes. Age, frequency of female
7 sex, atherosclerotic risk factors, NIHSS score, degrees of PVH and DSWMH, and levels
8 of glucose and LDL-C were not significantly different between cryptogenic stroke and
9 other stroke subtypes. D-dimer levels were lower in cryptogenic stroke than in other
10 stroke subtypes (2.0 ± 4.2 vs. 2.3 ± 12.8 $\mu\text{g/mL}$, $P=0.048$) (Table 1).

11

12 **Clinical characteristics of cryptogenic stroke patients with stroke recurrence in the** 13 **negative RLS, RLS, and high-risk PFO groups**

14 In cryptogenic stroke, the median follow-up was 4.2 (interquartile range, 1.0–6.1)
15 years, and 55 patients had stroke recurrence. The negative RLS, RLS, and high-risk
16 PFO groups included 179, 90, and 60 patients, respectively (Fig. 1). Table 2 shows that
17 there were 35 patients with recurrent stroke in the negative RLS group. The frequency
18 of a previous history of ischemic stroke was relatively higher in patients with stroke
19 recurrence (25.7% vs. 13.9%, $P=0.089$), whereas the frequency of large infarct >3.0 cm
20 in diameter was relatively lower in patients with stroke recurrence, compared to patients
21 without stroke recurrence (14.3% vs. 27.8%, $P=0.098$). In the RLS group, 9 patients had
22 recurrent stroke, and the degrees of PVH and DSWMH were significantly higher in
23 patients with stroke recurrence than in patients without stroke recurrence (1.8 ± 0.8 vs.
24 0.8 ± 0.9 , $P=0.002$; 1.7 ± 0.9 vs. 0.7 ± 0.8 , $P=0.001$). In the high-risk PFO group, 11

1 patients had stroke recurrence, and the NIHSS score on admission (2 [1.5-4.5] vs. 1 [0-
2 3], $P=0.053$) was relatively higher than in patients without stroke recurrence. Degrees of
3 PVH and DSWMH were significantly higher in patients with stroke recurrence than in
4 patients without stroke recurrence (1.7 ± 1.0 vs. 0.8 ± 1.0 , $P=0.003$; 1.3 ± 1.0 vs. 0.7 ± 0.8 ,
5 $P=0.041$).

6

7 **Factors associated with stroke recurrence according to the presence of RLS**

8 The incidence of stroke recurrence in the three groups was 5.3%, 2.5%, and 4.6% per
9 person-year, respectively. In the negative RLS group, dyslipidemia, previous history of
10 ischemic stroke, multiple infarctions, and large infarct > 3.0 cm reached $P<0.2$ on
11 univariate Cox hazards analysis and were entered into the multivariate Cox hazards
12 analysis. However, no factors were found to predict stroke recurrence (Table 3). In the
13 RLS group, the univariate Cox hazards analysis showed that PVH and DSWMH
14 significantly predicted stroke recurrence (hazard ratio [HR] 2.319, 95% CI 1.257-4.277,
15 $P=0.007$; HR 2.506, 95% CI 1.349-4.654, $P=0.004$). However, multivariate analysis
16 found no factors predicting stroke recurrence (Table 4). In the high-risk PFO group,
17 NIHSS score on admission (HR 1.346, 95% CI 1.147-1.579, $P<0.001$), PVH (HR 2.520,
18 95% CI 1.417-4.484, $P=0.002$), and DSWMH (HR 2.547, 95% CI 1.296-5.008,
19 $P=0.007$) showed significant differences and were entered into the multivariate Cox
20 hazards model. The NIHSS score on admission (HR 1.257, 95% CI 1.034-1.530,
21 $P=0.022$) and PVH (HR 3.369, 95% CI 1.103-10.294, $P=0.035$) were found to be
22 predictive markers for stroke recurrence (Table 5). The Kaplan-Meier survival curves
23 showed that cumulative event-free rates were significantly lower in patients with a

1 higher degree of PVH in patients with RLS (log-rank test, $P=0.029$) and with high-risk
2 PFO (log-rank test, $P=0.004$) (Fig. 2).

3 **Treatment for cryptogenic stroke patients according to the presence of RLS**

4 As for secondary prevention of cryptogenic stroke, antiplatelet agents and
5 anticoagulant therapy were given in 86.0% and 15.1%, 72.2% and 27.8%, and 60.0%
6 and 41.7% of the negative RLS, RLS, and high-risk PFO groups, respectively (Fig. 3).

7

8 **Discussion**

9 The current study from a multicenter registry of stroke patients undergoing TEE with
10 long-term outcomes provides novel insights into the clinical significance of stroke
11 recurrence in cryptogenic stroke patients according to the presence of RLS. The rate of
12 stroke recurrence was higher in order of negative RLS, high-risk PFO, and RLS. In
13 particular, the presence of white matter lesions was a predictive factor for stroke
14 recurrence in high-risk PFO, whereas there was relative linkage between RLS and
15 stroke recurrence, and no specific factors were associated with stroke recurrence in
16 negative RLS.

17 There has been considerable interest in risk stratification for stroke recurrence in
18 patients with PFO. With the RoPE (Risk of Paradoxical Embolism) score, higher points,
19 indicating PFO-attributable strokes, predicted a lower stroke recurrence rate.¹⁴
20 Meanwhile, the presence of a concomitant ASA increased the risk of stroke recurrence
21 in patients with PFO. Mas et al. analyzed the stroke recurrence rate over four years in
22 581 patients with cryptogenic stroke ≤ 55 years of age and with treatment of aspirin 300
23 mg/day; the stroke recurrence rate was 15.2% in patients with both PFO and ASA, 2.3%
24 in patients with PFO alone, and 4.2% in patients with neither PFO nor ASA.⁴ The

1 present registry study showed that cryptogenic stroke patients with high-risk PFOs had
2 a 1.8 times higher stroke recurrence rate than cryptogenic stroke patients with RLS, but
3 lower than that in the negative RLS group. Compared to the study by Mas et al., the
4 patients enrolled in the present study were older and frequently had atherosclerotic
5 vascular risk factors, leading to the presence of other embologenic diseases such as
6 aortic complicated plaques and non-stenotic carotid plaques, which could be a cause of
7 the higher rate of stroke recurrence in the negative RLS group. More importantly, high-
8 risk PFO could be a risk factor for stroke recurrence in cryptogenic stroke over the
9 entire age spectrum, particularly when comparing with RLS other than with high-risk
10 PFO.

11 PVH and DSWMH have been shown as degrees of cerebral white matter lesions.¹¹
12 Aging and hypertension are fundamental risk factors for the development of white
13 matter diseases.¹¹ Conversely, we previously reported the association of PVH with PFO,
14 and in particular, the co-existence of PFO and ASA was associated with a higher degree
15 of white matter lesions than lone PFO, lone ASA, and neither of them.¹⁵ Several studies
16 showed that PFO contributed to the development of white matter lesions in Alzheimer's
17 disease and decompression disease.^{16, 17} Conversely, no such relationship was found in
18 patients with migraine and cerebral autosomal dominant arteriopathy with subcortical
19 infarcts and leukoencephalopathy.^{18, 19} In addition, cerebral perforating arteries can be
20 occluded by small emboli,²⁰ even paradoxical emboli.²¹ Thus, small emboli derived
21 from a septal abnormality or the venous system might be related to recurrent stroke and
22 the development of white matter lesions.

23 Regarding treatment, patients who developed stroke by 2017, when percutaneous
24 PFO closure was not approved in Japan, were enrolled. The frequency of antiplatelet

1 therapy for secondary prevention was higher in the order of negative RLS, RLS, and
2 high-risk PFO groups, whereas the frequency of anticoagulant therapy was the opposite.
3 It is well known that large-scale clinical trials failed to show the efficacy of direct oral
4 anticoagulant (DOAC) therapy for embolic stroke of undetermined source (ESUS),^{22, 23}
5 and a recent systematic review demonstrated that the majority of patients received
6 antiplatelet therapy in ESUS.²⁴ There are two possible explanations for selecting
7 anticoagulant therapy in cryptogenic stroke. However, the present registry did not
8 include the presence of deep venous thrombosis, which existed in some patients in the
9 RLS and high-risk PFO groups. Alternatively, some studies indicated that anticoagulant
10 therapy was partially effective for cryptogenic stroke patients.^{25, 26}

11 Some potential limitations of the current study must be considered when interpreting
12 its results. First, due to the retrospective nature of the study design and data extraction
13 procedure, small amounts of data were missing or unavailable. Second, selection bias
14 for the performance of TEE might have been involved in each hospital. Although the
15 protocols for TEE and the interpretations of these findings were common in the two
16 institutions, there was a lack of standardization.

17 In conclusion, PVH can be a prognostic marker for stroke recurrence in cryptogenic
18 stroke with high-risk PFO, for whom careful monitoring and PFO closure might be
19 considered at <60 years of age.

20

21 **Acknowledgments**

22 None

23 **Funding**

1 This work was funded, in part, by the BMS/Pfizer Japan Thrombosis Investigator

2 Initiated Research Program (JRISTA).

3 **Potential Conflicts of Interest**

4 None declared.

5 **Data availability statement**

6 The datasets used and analyzed during the current study are available from the

7 corresponding author on reasonable request.

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

1 Reference

- 2 1. Di Tullio MR. Patent foramen ovale: Echocardiographic detection and
3 clinical relevance in stroke. *J Am Soc Echocardiogr.* 2010;23:144-155;
4 quiz 220
- 5 2. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent
6 foramen ovale during the first 10 decades of life: An autopsy study of 965
7 normal hearts. *Mayo Clin Proc.* 1984;59:17-20
- 8 3. Mazzucco S, Li L, Binney L, Rothwell PM, Oxford Vascular Study
9 Phenotyped C. Prevalence of patent foramen ovale in cryptogenic
10 transient ischaemic attack and non-disabling stroke at older ages: A
11 population-based study, systematic review, and meta-analysis. *Lancet*
12 *Neurol.* 2018;17:609-617
- 13 4. Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, et al.
14 Recurrent cerebrovascular events associated with patent foramen ovale,
15 atrial septal aneurysm, or both. *N Engl J Med.* 2001;345:1740-1746
- 16 5. Mazzucco S, Li L, Rothwell PM. Prognosis of cryptogenic stroke with
17 patent foramen ovale at older ages and implications for trials: A
18 population-based study and systematic review. *JAMA Neurol.*
19 2020;77:1279-1287
- 20 6. Shimada Y, Ueno Y, Tanaka Y, Okuzumi A, Miyamoto N, Yamashiro K,
21 et al. Aging, aortic arch calcification, and multiple brain infarcts are
22 associated with aortogenic brain embolism. *Cerebrovasc Dis.*
23 2013;35:282-290

- 1 7. Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS,
2 et al. Long-term outcomes of patent foramen ovale closure or medical
3 therapy after stroke. *N Engl J Med*. 2017;377:1022-1032
- 4 8. Sondergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK,
5 Nielsen-Kudsk JE, et al. Patent foramen ovale closure or antiplatelet
6 therapy for cryptogenic stroke. *N Engl J Med*. 2017;377:1033-1042
- 7 9. Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L,
8 et al. Patent foramen ovale closure or anticoagulation vs. Antiplatelets
9 after stroke. *N Engl J Med*. 2017;377:1011-1021
- 10 10. Lee PH, Song JK, Kim JS, Heo R, Lee S, Kim DH, et al. Cryptogenic
11 stroke and high-risk patent foramen ovale: The defense-pfo trial. *J Am*
12 *Coll Cardiol*. 2018;71:2335-2342
- 13 11. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. Mr signal
14 abnormalities at 1.5 t in alzheimer's dementia and normal aging. *AJR Am*
15 *J Roentgenol*. 1987;149:351-356
- 16 12. Ueno Y, Tateishi Y, Doijiri R, Kuriki A, Shimizu T, Kikuno M, et al. Large
17 aortic arch plaques correlate with chads2 and cha2ds2-vasc scores in
18 cryptogenic stroke. *Atherosclerosis*. 2019;284:181-186
- 19 13. Adams HP, Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL,
20 et al. Classification of subtype of acute ischemic stroke. Definitions for
21 use in a multicenter clinical trial. Toast. Trial of org 10172 in acute stroke
22 treatment. *Stroke*. 1993;24:35-41

- 1 14. Kent DM, Ruthazer R, Weimar C, Mas JL, Serena J, Homma S, et al. An
2 index to identify stroke-related vs incidental patent foramen ovale in
3 cryptogenic stroke. *Neurology*. 2013;81:619-625
- 4 15. Ueno Y, Shimada Y, Tanaka R, Miyamoto N, Tanaka Y, Hattori N, et al.
5 Patent foramen ovale with atrial septal aneurysm may contribute to white
6 matter lesions in stroke patients. *Cerebrovasc Dis*. 2010;30:15-22
- 7 16. Purandare N, Oude Voshaar RC, McCollum C, Jackson A, Burns A.
8 Paradoxical embolisation and cerebral white matter lesions in dementia.
9 *Br J Radiol*. 2008;81:30-34
- 10 17. Gerriets T, Tetzlaff K, Hutzelmann A, Liceni T, Kopske G, Struck N, et al.
11 Association between right-to-left shunts and brain lesions in sport divers.
12 *Aviat Space Environ Med*. 2003;74:1058-1060
- 13 18. Adami A, Rossato G, Cerini R, Thijs VN, Pozzi-Mucelli R, Anzola GP, et
14 al. Right-to-left shunt does not increase white matter lesion load in
15 migraine with aura patients. *Neurology*. 2008;71:101-107
- 16 19. Zicari E, Tassi R, Stromillo ML, Pellegrini M, Bianchi S, Cevenini G, et al.
17 Right-to-left shunt in cadasil patients: Prevalence and correlation with
18 clinical and mri findings. *Stroke*. 2008;39:2155-2157
- 19 20. Cacciatore A, Russo LS, Jr. Lacunar infarction as an embolic
20 complication of cardiac and arch angiography. *Stroke*. 1991;22:1603-
21 1605
- 22 21. Otto AM, Ciampa ML, Martin ED. Lacunar cerebral infarction following
23 endovascular interventions for phlegmasia cerulea dolens. *J Vasc Surg*
24 *Cases Innov Tech*. 2021;7:536-539

- 1 22. Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD,
2 et al. Rivaroxaban for stroke prevention after embolic stroke of
3 undetermined source. *N Engl J Med*. 2018;378:2191-2201
- 4 23. Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama
5 S, et al. Dabigatran for prevention of stroke after embolic stroke of
6 undetermined source. *N Engl J Med*. 2019;380:1906-1917
- 7 24. Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ. Embolic stroke
8 of undetermined source: A systematic review and clinical update. *Stroke*.
9 2017;48:867-872
- 10 25. Sacco RL, Prabhakaran S, Thompson JL, Murphy A, Sciacca RR, Levin
11 B, et al. Comparison of warfarin versus aspirin for the prevention of
12 recurrent stroke or death: Subgroup analyses from the warfarin-aspirin
13 recurrent stroke study. *Cerebrovasc Dis*. 2006;22:4-12
- 14 26. Kasner SE, Swaminathan B, Lavados P, Sharma M, Muir K, Veltkamp R,
15 et al. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke
16 of undetermined source: A prespecified subgroup analysis from the
17 navigate esus trial. *Lancet Neurol*. 2018;17:1053-1060

18
19
20
21
22
23
24
25
26
27
28

Table 1. Baseline characteristics, MRI findings, and laboratory data of the cryptogenic stroke and other stroke subtype groups

Characteristics	Cryptogenic stroke n=329, 56%	Other stroke subtype n=257, 44%	<i>P</i>
Sociodemographic			
Age, y, mean±SD	65.6±13.4	65.4±12.9	0.794
Gender, female, no (%)	112 (34.0)	73 (28.4)	0.145
Risk factors, no (%)			
Hypertension	210 (63.8)	175 (68.1)	0.281
Diabetes Mellitus	96 (29.2)	78 (30.4)	0.111
Dyslipidemia	151 (49.2)	135 (52.5)	0.758
Cigarette smoking	77 (23.4)	59 (23.0)	0.899
Coronary artery disease	25 (7.6)	30 (11.7)	0.093
Chronic kidney disease	80 (24.3)	72 (28.0)	0.311
Previous history of ischemic stroke	50 (15.2)	47 (18.3)	0.318
NIHSS on admission, median (IQR) ^a	2 (1-3)	2 (0-3)	0.09
MRI			
PVH, Fazeka's grade	1.0±0.9	0.9±0.8	0.123
DSWMH	0.9±0.9	0.8±0.8	0.605
Laboratory data			
Glucose, mg/dL	125.8±44.0	127.2±53.9	0.802
LDL-C, mg/dL	115.1±36.3	116.9±35.4	0.36
D-dimer, µg/mL	2.0±4.2	2.3±12.8	0.048

Chi-square test, and the Mann-Whitney test were used for comparison. MRI = Magnetic Resonance Imaging, SD = standard deviation, NIHSS = National Institute of Health Stroke Scale, IQR = interquartile range, PVH = periventricular hyperintensity, LDL-C = low-density lipoprotein cholesterol. Missing value: a) = 17, b) =4, c) = 18, d) = 16.

1

2

Table 2. Baseline characteristics, MRI findings, and laboratory data according to the presence of stroke recurrence in cryptogenic stroke with negative RLS, RLS, and high-risk PFO

Characteristics	Negative RLS, stroke recurrence			RLS, stroke recurrence			High-risk PFO, stroke recurrence		
	Positive n=35, 20%	Negative n=144, 80%	<i>P</i>	Positive n=9, 10%	Negative n=81, 90%	<i>P</i>	Positive n=11, 18%	Negative n=49, 82%	<i>P</i>
Sociodemographic									
Age, y, mean±SD	68.1±14.0	66.7±12.7	0.765	68.7±9.6	62.3±15.0	0.336	69.4±11.6	64.7±13.0	0.181
Gender, female, no (%)	14 (40.0)	52 (36.1)	0.669	3 (33.3)	26 (32.1)	0.764	4 (36.4)	13 (26.5)	0.777
Risk factors, no (%)									
Hypertension	27 (77.1)	101 (70.1)	0.41	7 (77.8)	44 (54.3)	0.321	8 (72.7)	23 (46.9)	0.225
Diabetes Mellitus	10 (28.6)	52 (32.6)	0.4	2 (22.2)	22 (27.2)	0.937	3 (27.3)	7 (14.3)	0.551
Dyslipidemia	22 (62.9)	44 (51.4)	0.222	2 (22.2)	31 (38.3)	0.56	6 (54.5)	16 (32.7)	0.31
Cigarette smoking	7 (20.0)	32 (22.2)	0.775	0 (0)	20 (24.7)	0.205	3 (27.3)	15 (30.6)	0.884
Coronary artery disease	3 (8.6)	11 (7.6)	0.868	0 (0)	8 (9.9)	0.711	1 (9.1)	2 (4.1)	0.939
Chronic kidney disease	12 (34.3)	42 (29.2)	0.554	3 (33.3)	14 (17.3)	0.473	2 (18.2)	7 (14.3)	0.305
Previous history of ischemic stroke	9 (25.7)	20 (13.9)	0.089	2 (22.2)	9 (11.1)	0.668	3 (27.3)	7 (14.3)	0.551
NIHSS on admission, median (IQR), a)	2 (1-3)	2 (1-3.75)	0.997	2 (2-2)	2 (0.25-3)	0.697	2 (1.5-4.5)	1 (0-3)	0.053
MRI									
Multiple infarctions, no (%)	20 (57.1)	65 (45.1)	0.202	20 (57.1)	65 (45.1)	0.778	5 (45.5)	22 (44.9)	0.763
Large infarct > 3.0 cm in diameter, no (%)	5 (14.3)	40 (27.8)	0.098	2 (22.2)	19 (23.5)	0.74	3 (27.3)	10 (20.4)	0.925
PVH, Fazeka's grade	1.3±1.0	1.1±0.9	0.474	1.8±0.8	0.8±0.9	0.002	1.7±1.0	0.8±1.0	0.003
DSWMH, Fazeka's grade	1.0±0.8	0.9±0.8	0.712	1.7±0.9	0.7±0.8	0.001	1.3±1.0	0.7±0.8	0.041
Laboratory data									
Glucose, mg/dL, b)	118.6±33.9	125.4±43.1	0.562	139.4±48.6	128.0±46.6	0.393	128.7±36.7	125.1±50.0	0.175
LDL-C, mg/dL, c)	111.3±34.2	116.5±38.3	0.399	105.0±36.4	115.3±34.3	0.443	113.5±31.1	115.5±37.4	0.77
D-dimer, µg/mL, d)	1.7±1.6	2.2±5.5	0.909	1.3±0.9	1.6±2.0	0.873	2.2±2.8	2.4±4.5	0.882

Chi-square test, and the Mann-Whitney test were used for comparison. MRI = Magnetic Resonance Imaging, RLS = light to left shunt, PFO = patent foramen ovale, SD = standard deviation, NIHSS = National Institute of Health Stroke Scale, IQR = interquartile range, PVH = periventricular hyperintensity, LDL-C = low-density lipoprotein

cholesterol.Missing value: a) = 13, b) =4, c) = 14, d) = 11.

Table 3. Univariate and multivariate analyses of baseline characteristics, MRI findings, and laboratory data predicting stroke recurrence in cryptogenic stroke without RLS

Characteristics	Univariate analysis			Multivariate analysis		
	HR	95% CI	<i>P</i>	HR	95% CI	<i>P</i>
Sociodemographic						
Age	1.011	0.984-1.039	0.417			
Gender, female	1.162	0.591-2.288	0.663			
Risk factors						
Hypertension	1.083	0.491-2.390	0.843			
Diabetes Mellitus	0.727	0.349-1.513	0.394			
Dyslipidemia	1.606	0.808-3.191	0.176	1.694	0.847-3.388	0.136
Cigarette smoking	0.835	0.364-1.916	0.67			
Coronary artery disease	0.937	0.286-3.064	0.914			
Chronic kidney disease	1.289	0.640-2.596	0.477			
Previous history of ischemic stroke	1.925	0.899-4.122	0.092	1.831	0.852-3.935	0.121
NIHSS on admission, a)	0.932	0.809-1.073	0.326			
MRI						
Multiple infarctions	1.754	0.894-3.442	0.102	1.723	0.874-3.396	0.116
Large infarct > 3.0 cm in diameter	0.493	0.191-1.272	0.143	0.477	0.184-1.240	0.129
PVH	1.225	0.855-1.756	0.27			
DSWMH	1.138	0.765-1.692	0.524			
Laboratory data						
Glucose, b)	0.994	0.985-1.004	0.229			
LDL-C, c)	0.997	0.987-1.007	0.542			
D-dimer, d)	1.023	0.925-1.131	0.661			
Treatment						
Antiplatelet agent	1.463	0.516-4.146	0.474			
Anticoagulant therapy	0.691	0.244-1.957	0.486			

MRI = Magnetic Resonance Imaging, RLS = light to left shunt, HR = hazard ratio, CI = confidence interval NIHSS = National Institute of Health Stroke Scale, PVH = periventricular hyperintensity, LDL-C = low-density lipoprotein cholesterol. Missing value: a) = 13, b) = 4, c) = 14, d) = 11.

Table 4. Univariate and multivariate analyses of baseline characteristics, MRI findings, and laboratory data predicting stroke recurrence in cryptogenic stroke with RLS

Characteristics	Univariate analysis			Multivariate analysis		
	HR	95% CI	P	HR	95% CI	P
Sociodemographic						
Age	1.04	0.981-1.103	0.191	1.011	0.950-1.077	0.728
Gender, female	1.043	0.261-4.174	0.952			
Risk factors						
Hypertension	2.793	0.580-13.448	0.2			
Diabetes Mellitus	0.801	0.166-3.859	0.782			
Dyslipidemia	0.459	0.095-2.209	0.331			
Cigarette smoking	0.031	0.000-17.945	0.285			
Coronary artery disease	0.043	0.000-869.328	0.534			
Chronic kidney disease	2.111	0.527-8.463	0.291			
Previous history of ischemic stroke	1.796	0.373-8.651	0.465			
NIHSS on admission, a)	0.982	0.848-1.137	0.808			
MRI						
Multiple infarctions	1.575	0.423-5.868	0.498			
Large infarct > 3.0 cm in diameter	1.004	0.208-4.835	0.996			
PVH	2.319	1.257-4.277	0.007	1.088	0.195-6.063	0.923
DSWMH	2.506	1.349-4.654	0.004	2.244	0.403-12.499	0.356
Laboratory data						
Glucose, b)	1.003	0.991-1.015	0.623			
LDL-C, c)	0.986	0.962-1.010	0.26			
D-dimer, d)	0.943	0.482-1.845	0.865			
Treatment						
Antiplatelet agent	1.442	0.299-6.943	0.648			
Anticoagulant therapy	0.742	0.154-3.576	0.71			

MRI = Magnetic Resonance Imaging, RLS = light to left shunt, HR = hazard ratio, CI = confidence interval NIHSS = National Institute of Health Stroke Scale, PVH = periventricular hyperintensity, LDL-C = low-density lipoprotein cholesterol. Missing value: a) = 13, b) = 4, c) = 14, d) = 11.

Table 5. Univariate and multivariate analyses of baseline characteristics, MRI findings, and laboratory data predicting stroke recurrence in cryptogenic stroke with high-risk PFO

Characteristics	Univariate analysis			Multivariate analysis		
	HR	95% CI	<i>P</i>	HR	95% CI	<i>P</i>
Sociodemographic						
Age	1.034	0.973-1.0099	0.276			
Gender, female	1.913	0.558-6.558	0.302			
Rsk factors						
Hypertension	2.374	0.629-8.955	0.202			
Diabetes Mellitus	1.742	0.462-6.574	0.413			
Dyslipidemia	2.058	0.627-6.753	0.234			
Cigarette smoking	0.785	0.208-2.961	0.721			
Coronary artery disease	1.472	0.186-11.623	0.714			
Chronic kidney disease	1.297	0.280-6.006	0.74			
Previous history of ischemic stroke	2.61	0.682-9.993	0.161	1.687	0.268-10.620	0.577
NIHSS on admission, a)	1.346	1.147-1.579	<0.001	1.257	1.034-1.530	0.022
MRI						
Multiple infarctions	1.076	0.328-3.532	0.904			
Large infarct > 3.0 cm in diameter	1.281	0.339-4.841	0.715			
PVH	2.52	1.417-4.484	0.002	3.369	1.103-10.294	0.035
DSWMH	2.547	1.296-5.008	0.007	0.392	0.088-1.754	0.221
Laboratory data						
Glucose, b)	1.003	0.991-1.015	0.645			
LDL-C, c)	1	0.985-1.016	0.962			
D-dimer, d)	1.029	0.872-1.214	0.737			
Treatment						
Antiplatelet agent	2.574	0.677-9.779	0.165	2.964	0.428-20.545	0.271
Anticoagulant therapy	0.445	0.118-1.689	0.234			

MRI = Magnetic Resonance Imaging, PFO = patent foramen ovale, HR = hazard ratio, CI = confidence interval NIHSS = National Institute of Health Stroke Scale, PVH = periventricular hyperintensity, DSWMH = deep and subcortical white matter hyperintensity, LDL-C = low-density lipoprotein cholesterol. Missing value: a) = 13, b) = 4, c) = 14, d) = 11.

Figure legends

Figure 1. COCTAIL-TEE = Clinical Observation, Characteristics, and prognosis for long-term of stroke patients undergoing TransEsophageal Echocardiography, RLS = right-to-left shunt, PFO = patent foramen ovale.

Figure 2. Kaplan-Meier curves of freedom from stroke recurrence during follow-up. The X axis indicates time in days since inclusion in the study. The Y axis indicates the proportion of patients surviving free of stroke recurrence. Cumulative event-free rates are compared among degrees of periventricular hyperintensity in the negative RLS (A), RLS (B), and high-risk PFO (C) groups. RLS = right-to-left shunt, PFO = patent foramen ovale.

Figure 3. Proportion of antiplatelet and anticoagulant therapies for secondary prevention in the negative RLS, RLS, and high-risk PFO groups.

ACT = anticoagulant therapy, APT = antiplatelet therapy, RLS = right-to-left shunt, PFO = patent foramen ovale.





